PAO Group, Inc. (USOTC: PAOG) today announced executing a master services agreement with a clinical research organization in the U.S. to prepare PAOG for initiating an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG signed the agreement yesterday, prior to the comprehensive corporate update scheduled for publication today and included in its entirety below. Source:…
Read MoreAuthor: The Motley Fool
The Motley Fool is dedicated to helping the world invest — better. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, mutual funds, and premium investing services.
In all we do, we take a different approach.
We believe – and have proven over decades – that the individual investor can beat the market.
We believe that anyone can do it, even if they don’t have a lot of time or money to devote to investing.
We believe in a long-term outlook, helping people build wealth over time.
We believe that the person best positioned to take care of your financial future is you.
And we work tirelessly on behalf of our hundreds of thousands of members who are enjoying the opportunities that come with having enough money to do the things that matter to them.
While we are headquartered in Alexandria, Va., The Motley Fool advocates for the individual investor around the globe with offices in the UK, Australia, Canada, Singapore, and Germany.
PAOG – New Independent CBD Research Appears To Support PAOG RespRx Research
PAO Group, Inc. (USOTC: PAOG) today highlighted an article just released from Life Sciences: Source: Kaly PAOG – New Independent CBD Research Appears To Support PAOG RespRx Research Kaly
Read MorePAOG FDA Application Process For Respiratory Cannabis Drug Treatment Update Scheduled This Friday
PAO Group, Inc. (USOTC: PAOG) today announced the company plans to release a new key update this Friday, October 23, 2020, on its progress to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). PAOG announced last week that it anticipates soon entering into an agreement with a contract research organization (CRO) making a major…
Read MoreIf You Only Buy 1 Pot Stock, This Should Be It
Pot stocks had an amazing 2018. Several upstarts became multi-billion dollar giants. The cannabis industry saw valuations double, triple, and then quadruple in a matter of months. Those days are long over. In 2019, the industry entered its first bear market. Any hopes of a recovery in 2020 were dashed by the coronavirus pandemic. Today, valuations are at rock bottom.…
Read MorePAOG and PURA Announce Free Hemp Seed Giveaway To Promote CBD and Hemp Awareness
Sandusky, Ohio–(Newsfile Corp. – October 16, 2020) – PAO Group, Inc. (OTC Pink: PAOG) and Puration, Inc. (OTC Pink: PURA) today announced a free hemp seed giveaway in conjunction with the recent partnership between the two companies where PAOG will be building a hemp cultivation facility on PURA’s Farmersville, Texas property. HEMPTo view an enhanced version of this graphic, please…
Read MoreIs This $375 Million Cannabis Stock Too Good to Be True?
Following the industry bear market of 2019, many thought cannabis stocks would recover. Then came the coronavirus pandemic. Today, valuations remain 80% below their peak. Marijuana companies are still hurting. Just look at Hexo (TSX:HEXO)(NYSE:HEXO). This $375 million business was once valued at $2 billion! But this is far from the end. Marijuana consumption continues to rise, and companies are figuring…
Read MoreHere Are 3 TSX Stocks to Sell if Joe Biden Becomes President
United States citizens and international onlookers were treated to the first debate between U.S. president Donald Trump and his challenger Democratic nominee Joe Biden on September 29. Last month, I’d discussed how a chaotic U.S. election could have a negative impact on domestic and global equities. The debate was one of the wildest and most contentious in modern history. Regardless,…
Read MorePAOG Engages Saul Kaye, Founder of iCAN: Israel-Cannabis and CannaTech to Prepare RespRx for IND
Sandusky, Ohio–(Newsfile Corp. – October 1, 2020) – PAO Group, Inc. (OTC Pink: PAOG) today announced engaging Saul Kaye, the founder of iCAN (www.israel-cannabis.com) and CannaTech (www.canna-tech.co) to provide an independent review of PAOG’s RespRx research for the treatment of Chronic Obstructive Pulmonary Disease (COPD), and to help prepare RespRx for engaging with a contract research organization (CRO) to advance…
Read More1 Pot Stock to Buy Before the Next Surge
Pot stocks had a heyday in 2018. That year, cannabis companies saw their shares double, triple, or even quadruple in price. The industry minted countless millionaires in a handful of months. Things changed quickly. In 2019, cannabis stocks entered a rough bear market. The coronavirus pandemic of 2020 pushed valuations even lower. Right now, many marijuana investors are jaded and…
Read MorePAOG Expands Cannabis Pharma Treatment Research
Sandusky, Ohio–(Newsfile Corp. – September 24, 2020) – PAO Group, Inc. (OTC Pink: PAOG) today announced the company will expand its cannabis pharmaceutical treatment research beyond its current focus on Chronic Obstructive Pulmonary Disease (COPD).On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for COPD derived from a patented…
Read More